73 results about "Diaryl ether" patented technology

A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3′, E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.

The present invention provides diaryl ether derivatives that exhibit significant immunosuppressive effects with less side effects.The diaryl derivatives of the present invention are represented by the following general formula (1): one example is 2-amino-2-[4-(3-benzyloxyphenoxy)-2-chlorophenyl]propyl-1,3-propanediol.

A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3′, E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed

A medicine which effectively functions as an immunosuppressant or anti-inflammatory agent and is effective in diminishing the occurrence of side effects. The medicine comprises a combination of: a diaryl sulfide or diaryl ether compound having a 2-amino-1,3-propanediol structure and having the function of diminishing lymphocytes circulating through the periphery; and an immunosuppressant and / or an anti-inflammatory agent.

The invention relates to formula (I) N-substituted aromatic hydrocarbon phenyl amines and polysubstitution diaryl ether compounds or medicinal salt thereof, wherein, definitions of X, Y, Z, R1-R4 are shown in a claim, and also relates to a preparing method thereof, a drug combination containing the compounds and the application to anti cancer drug preparation thereof.

The invention discloses a method for synthesizing asymmetric diaryl ether derivative with a structure shown in a structural formula (I), comprising the following steps: making arylboronic acid and nitrobenzene compound which are raw materials to fully react in an inert organic solvent in the presence of a copper catalyst, an additive and an alkaline compound at 30-150 DEG C, wherein the arylboronic acid has the structural formula (II), and the nitrobenzene compound has the structural formula (III); and postprocessing, separating and purifying a reaction solution after the reaction finishes to obtain the asymmetric diaryl ether derivative. The method for synthesizing the asymmetric diaryl ether derivative has the advantages of mild reaction condition, high reaction yield, good selectivity and low-cost generation cost.

A preparation method for 3,4'dichloro diaryl ether is disclosed, which comprises the following steps of: (1) preparation for potassium alkoxide or sodium alkoxide; (2) preparation for potassium p-chlorophenolate; (3) preparation for active cuprous chloride; and (4) preparation for 3,4'dichloro diaryl ether. The preparation method has the following advantages that: side reactions are greatly reduced, reaction speed is fast, the pollution caused by the volatilization of benzene solvents is reduced, the utilization rate of equipment and the like are increased, the quality of product is improved, as well as yield and chilling efficiency are increased by using p-chlorophenol waterless salifying process, using newly-prepared catalyst, optimizing the ratio and pouring method of materials, and protecting by inert gas.

A process using amino acids as additive for synthesizing biarylether features use of amino acid as additive and Cu salt as catalyst. The said amino acid may be the monosubstituted (or bisubstituted)-on-nitrogen alpha-amino acid or beta-amino acid. Its advantages are very gentle reaction, condition and high output rate.

The invention provides novel β2 adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with β2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.

The invention discloses a 1-3 generation arylene ether-substituted dendritic phthalocyanine zinc complex, a preparation method and an application thereof. The method comprises the following steps of adopting a Frechet synthesis method to synthesize the first to third generation alcohol molecules which take the 1-3 generation cyan as an end group; leading the first to third generation alcohols to react with 4-nitrophthalonitrile respectively, thus synthesizing corresponding phthalocyanine precursor of dendrimer taking the 1-3 generation cyan as the end group; subsequently, leading the phthalocyanine precursor ring of dendrimer taking the 1-3 generation cyan as the end group to synthesize corresponding arylene ether dendritic phthalocyanine taking the first to third generation cyan as the end group and the arylene ether dendritic phthalocyanine taking the first to third generation carboxyl as the end group generated by hydrolysis. The 1-3 generation arylene ether dendritic phthalocyanine complex and the amphiphilic block copolymer are automatically dissolved to form the polymer nano-particle loading the 1-3 generation arylene ether dendritic phthalocyanine complex. The 1-3 generation diaryl ether dendritic phthalocyanine zinc complex and the loaded polymer nano-particle thereof are used as photosencitizers for photodynamic therapy.

A means and method for increasing or inhibiting the secretion of cytokines using gallotannins and ellagitannins is described. The preferred cytokine release inhibiting compounds are dimeric gallotannins having a linker molecule that misaligns the carbohydrate cores of the compounds. The preferred cytokine release promoting gallotannins and ellagitannins include a diaryl ether linker unit. In comparison to the more structurally complex ellagitannins, the compounds of this invention are structurally simpler, easier to synthesize, and more potent.

One aspect of the present invention relates to novel reaction conditions that allow the efficient synthesis of diaryl ethers from arenes bearing a leaving group and arenols under relatively mild conditions. Another aspect of the present invention relates to the dramatic effects of acidic activators on Ullmann-type couplings involving electron-poor and / or relatively insoluble substrates.

The invention relates to an olefinic polymerization catalyst, a preparation method and a polymerization method. The olefinic polymerization catalyst comprises three components: A is solid catalyst component, B is organo-aluminum compound, and C is external electron donor and organic silicon compound; wherein, the A component contains titanium, magnesium and chlorine elements as well as internal electron donor which is the combination of 2, 4- diaryl acid pentanediol ester (PBA) and 1, 3-diether (BMF), the combination of the PBA and 1, 4- diaryl ether (BN), or the combination of PBA and aromatic acid ester. The olefinic polymerization catalyst has higher catalytic activity, the activity of the catalyst used for propylene polymerization can be regulated within the range of 40.0-120.0Kg pp / gCat, and isotactic index and molecular weight distribution index of polypropylene are also can be adjusted within the wide range.

The invention discloses a method for synthesizing o-amino diaryl ether and o-amino diaryl sulfur ether. The method comprises the steps of: adding an iron and / or copper catalyst in solvent alcohol or water under the action of alkali, and carrying out open loop coupling reaction on catalytic aryl halide and benzoazole compound to prepare the o-amino diaryl ether or o-amino diaryl sulfur ether, wherein the reaction general formula is shown in the specification. The method for preparing the o-amino diaryl ether and o-amino diaryl sulfur ether by the coupling reaction is low in catalyst price, low in toxicity, direct to react, high in atom economy, wide and stable in substrate source and wide in application scope. Under the optimized reaction conditions, the separation yield of target products reaches up to 96%.

Provided is a method for preparing a diaryl ether compound through the dehydration of an aromatic alcohol compound in the presence of a dehydration catalyst. The dehydration catalyst comprises an oxide of yttrium.

Provided is a process for preparing a diaryl ether compound through the dehydration of an aromatic alcohol compound in the presence of a dehydration catalyst. The dehydration catalyst is an oxide of a light rare earth element, wherein the light earth element is lanthanum, praseodymium, neodymium, or mixtures thereof.

The invention relates to a preparation method for synthesizing compounds, particularly a method for synthesizing diaryl ether compounds. The invention aims to solve the problem of difficulty in implementing industrialized production due to the defects of complex preparation technique, strict reaction conditions, uncontrollable operation, too many byproducts, and high oxidation tendency and difficulty in storage of the catalyst used in reaction in the existing preparation method for synthesizing diaryl ether compounds. The method comprises the following steps: 1. preparing a diaryl ether compound crude product; and 2. purifying to obtain the diaryl ether compounds. By using the cupric salt which is easy to store and introducing the cheap ligand, the invention saves the cost and is simple to operate; and the invention has the advantages of mild reaction conditions, low temperature and high yield. The invention is used for synthesizing diaryl ether compounds.

The invention relates to a preparation method of a diaryl ether compound. Particularly, under catalysis of chitosan supported cuprous oxide, an arylation reaction used for phenols is achieved, the corresponding diaryl ether compound is obtained, the technological condition is simple, the yield is good, operability is high, and wide functional group durability is achieved.

Provided is a process for preparing a diaryl ether compound through the dehydration of an aromatic alcohol compound in the presence of a halogenated rare earth element oxide catalyst, providing a reaction vessel having loaded therein a rare earth element oxide; halogenating the rare earth element oxide with a halogen source to form an activated catalyst; and dehydrating an aromatic alcohol compound over the activated catalyst to form the diaryl ether compound, where the halogenating and dehydrating steps occur in the same vessel. The rare earth element oxide is an oxide of a light rare earth element, an oxide of a medium rare earth element, an oxide of a heavy rare earth element, an oxide of yttrium, or a mixture of two or more thereof.

The invention discloses a substituted diaryl ether compound. The structural formula of the compound is shown in the specification. In the structural formula, Z is -CH- or -N-; W is -CH-or -N-; Y is -O-, -CH2-, -NH- or -NRy-; R1 is one of hydrogen, halogen, NO2, CN, CF3, ORa, CORa, COORa, SO2Ra, SO2NRaRb, NRaRb, NRaCORb, a non-substituted / substituted C1-C4 alkyl group, a non-substituted / substituted aryl group and a non-substituted / substituted heterocyclic group; R2 is hydrogen, a non-substituted / substituted C1-C4 alkyl group, or halogen; and R is one of a non-substituted / substituted C1-C12 alkyl group, a non-substituted / substituted C3-C12 cycloalkyl group, a non-substituted / substituted C2-C12 alkenyl group, a non-substituted / substituted aryl group, substituted alkylamine, and a non-substituted / substituted heterocyclic group. The substituted diaryl ether compound can obviously inhibit the malignant proliferation phenotype of cancer cells, promotes the expression of cell apoptosis factor proteins, and provides a new potential anticancer drug.

The invention provides a novel preparation method of a diaryl ether compound. The method concretely comprises the steps of sequentially adding a compound 1, dimethyl sulfoxide, cesium carbonate and acompound 2 into a reactor; performing stirring for 10 to 60 minutes at room temperature; then, putting the materials into an oil bath pot with the reaction temperature of 70 to 120 DEG C; performing illumination by an incandescent light bulb; performing TLC detection on the reaction process; after the reaction is completed, performing filtering, extraction and column chromatography on reaction liquid to obtain a target compound; completing the preparation of the diaryl ether compound. By using the technical scheme, under the visible light induction, no transition metal catalyst and no ligand or photooxidant reducing agent are added; aryl halide and phenol derivatives take photocatalysis C-O crossed coupling reaction. The preparation method has the advantages that the conditions are mild and green; the efficiency is high; the cost is low; the operation is simple and convenient. The prepared compound is an important synthetic intermediate in the fields of biology, medicine and organic synthesis, particularly in an aspect of medicine synthesis.

Synthesis of diaryl ether in water phase is characterized by taking aryl halogenide and phenol as raw material, taking water as solvent, auxiliarily heating by micro-wave, taking carbonate, fluoride, borate and hydroxide of alkali metal or alkaline earth metal as alkali, and C-O coupling reacting under transition metal catalyzing condition or without transition metal catalyzing condition, with ligand or without ligand, with surface activator or without surface activator. It achieves short reacting time, simple operation, easy separation and good reacting environment.

The invention provides a synthesis method of a benzoxepine compound. A diarylether compound is efficiently synthesized through a reaction of a diaryl cyclic iodonium salt compound and a substrate containing a hydroxyl group, and the benzoxepine compound is obtained through intramolecular cyclization. The reaction operation is simple, the post-treatment is convenient, and the problems of low efficiency, harsh reaction conditions and the like of a conventional synthesis method are solved; the atom economy of the substrate is fully utilized; and the diarylether compound is efficiently obtained byusing the hydroxyl-containing compound and the diaryl cyclic iodonium salt at a certain temperature under the catalysis of cheap metal copper, intramolecular cyclization is carried out through further reaction, the highest yield of the obtained diarylether compound is 99%, and the highest yield of the benzoxepine compound is 95%.

Provided is a process for preparing a diaryl ether compound through the dehydration of an aromatic alcohol compound in the presence of a dehydration catalyst. The dehydration catalyst is an oxide of a heavy rare earth element, wherein the heavy rare earth element is terbium, dysprosium, holmium, erbium, thulium, ytterbium, lutetium, or mixtures thereof.

The invention relates to a macrocyclic lactam compound with a diaryl ether as a skeleton and a preparation method thereof, and mainly solves the technical problem that currently there are few macrocyclic lactam compounds with a diaryl ether as a skeleton. The technical scheme of the present invention: a macrocyclic lactam compound with a diaryl ether as a skeleton is characterized in that it has the following structural formula: R1 and R2 are alkyl, cycloalkyl, aryl or alkyl with heteroatoms and One of the substituents of aryl.

To provide a medicament which efficiently expresses an immunosuppressive agent or an anti-inflammatory agent and reduces expression of side effect.A medicament includes diaryl sulfide or diaryl ether compound having a 2-amino-1,3-propanediol structure having an activity of reducing lymphocytes circulating peripherally, in combination with an immunosuppressive agent and / or an anti-inflammatory agent.

The invention belongs to the technical field of medicine and particularly relates to diary ether derivatives having a general formula I, pharmaceutical salts, hydrates and solvates of the diary ether derivatives, polycrystal or eutectic crystal of the diary ether derivatives, precursors and derivatives having the same biological functions, a preparation method of the diary ether derivatives and application of compositions containing one or more of the compounds in preparation of related medicines for treating Aids. Pharmacological experiment results show that the compounds have remarkable activity of resisting HIV-1 virus, are capable of effectively inhibiting replication of MT-4 cell infected with HIV-1 virus and have relatively low cytotoxicity. The general formula I is shown in the specification.

A means and method for increasing or inhibiting the secretion of cytokines using gallotannins and ellagitannins is described. The preferred cytokine release inhibiting compounds are dimeric gallotannins having a linker molecule that misaligns the carbohydrate cores of the compounds. The preferred cytokine release promoting gallotannins and ellagitannins include a diaryl ether linker unit. In comparison to the more structurally complex ellagitannins, the compounds of this invention are structurally simpler, easier to synthesize, and more potent.

Provided is a method for preparing a diaryl ether compound through the dehydration of an aromatic alcohol compound in the presence of a halogenated rare earth element oxide catalyst, wherein the used dehydration catalyst may be regenerated by a halogenation step. The rare earth element oxide is an oxide of a light rare earth element, an oxide of a medium rare earth element, an oxide of a heavy rare earth element, an oxide of yttrium, or a mixtures of two or more thereof.

Diaryl ethers in which one of the aryl groups is a phenyl fused to a cycloalkyl or heterocyclic ring, to which is attached an acetic acid group, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that often accompany this disease, including insulin resistance, obesity and lipid disorders.